{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04679376",
            "orgStudyIdInfo": {
                "id": "22-007824"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Statins for the Treatment of NASH",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH)",
            "acronym": "STAT NASH",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "statins-for-the-treatment-of-nash"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-12-17",
            "studyFirstSubmitQcDate": "2020-12-17",
            "studyFirstPostDateStruct": {
                "date": "2020-12-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Manal F. Abdelmalek",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor\u00ae), is safe and effective in improving the features of NASH."
        },
        "conditionsModule": {
            "conditions": [
                "NASH - Nonalcoholic Steatohepatitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 70,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group 1: Atorvastatin Treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive atorvastatin for 96 weeks",
                    "interventionNames": [
                        "Drug: Atorvastatin"
                    ]
                },
                {
                    "label": "Group 2: Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive a placebo for 96 weeks",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Atorvastatin",
                    "description": "40 mg daily administered orally in tablet or capsule form",
                    "armGroupLabels": [
                        "Group 1: Atorvastatin Treatment"
                    ],
                    "otherNames": [
                        "Lipitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered daily orally in tablet or capsule form, contains no active medicine",
                    "armGroupLabels": [
                        "Group 2: Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in NASH as measured by improvement in NAS score Improvement in NAS score (\u2265 2 points) with no worsening in fibrosis stage (\u22651 point) OR improvement in fibrosis with no worsening of NASH (change in the NAS score of \u2264 0 points).",
                    "description": "One overall score of NASH improvement will be derived from improvement in NAS score OR no worsening in fibrosis.",
                    "timeFrame": "Baseline, 96 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "NASH resolution as measured by (diagnosis by pathologist) (from definite- to not- NASH).....",
                    "description": "Histological change from NASH to No NASH",
                    "timeFrame": "Baseline, 96 weeks"
                },
                {
                    "measure": "Change in fibrosis stage as measured by change in stage",
                    "description": "Ordinal variable",
                    "timeFrame": "Baseline, 96 weeks"
                },
                {
                    "measure": "Change in each component of NASH histologic features as measured by presence or ab presence or absence of features or their severity.",
                    "description": "Existing features may improve in severity or disappear as an indication of improvement of NASH.",
                    "timeFrame": "Baseline, 96 weeks"
                },
                {
                    "measure": "Change in serum aminotransferase (ALT) and aspartate aminotransferase (AST) levels as measured by plasma concentrations",
                    "timeFrame": "Baseline, 96 weeks"
                },
                {
                    "measure": "Change in makers of hepatic fibrosis markers as measured by (FIB-4,51 liver stiffness by Fibroscan\u00ae)",
                    "timeFrame": "Baseline, 96 weeks"
                },
                {
                    "measure": "Change in capture attention parameter (CAP) score (with Fibroscan\u00ae)",
                    "timeFrame": "Baseline, 96 weeks"
                },
                {
                    "measure": "Serum creatine phosphokinase (CPK) as measured by serum concentration",
                    "timeFrame": "Baseline, 96 weeks"
                },
                {
                    "measure": "Change in serum lipids as measured by serum concentration",
                    "timeFrame": "Baseline, 96 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Definite NASH on a liver biopsy obtained \u2264 90 days prior to randomization with a NAFLD activity score (NAS) of \u2265 4 with at least 1 in each component of the NAS according to NASH CRN grading52\n* Fibrosis stage \u2265 2 as assessed by liver biopsy\n* Not currently on statin therapy\n* Provision of written informed consent\n* Agree to use of effective contraceptive measures if female of child bearing potential.\n\nExclusion Criteria:\n\n* The presence of any of the following will exclude a subject from study enrollment: Any chronic liver disease other than NASH (i.e., drug-induced, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, hemochromatosis, A1AT deficiency, Wilsons disease)\n* Cirrhosis, as assessed clinically or histologically\n* Presence of vascular liver disease\n* BMI \u2264 25 kg/m2\n* Excessive alcohol use (\\> 20 g/day) within the past 2 years\n* AST or ALT \\> 250 U/L.\n* Type 1 diabetes mellitus\n* Bariatric surgery in the past 5 years.\n* Weight gain of \\> 5% in past 6 months or \\> 10% change in past 12 months.\n* Inadequate venous access\n* HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or HCV RNA positive.\n* Receiving an elemental diet or parenteral nutrition\n* Chronic pancreatitis or pancreatic insufficiency\n* Any history of complications of cirrhosis (i.e. ascites, hepatic encephalopathy, or portal hypertensive bleeding), even if absent or optimized with medical management at time of screening\n* Concurrent conditions: a) Inflammatory bowel disease, b) Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of screening, c) Ongoing infectious, immune mediated disease within previously 1 years, d) Any malignant disease (other than basal cell carcinoma of the skin) within previous 5 years, e) Prior solid organ transplant, f) Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or the interpretation of the study data.\n* Concurrent medications including: a) Anti-NASH therapy(s) initiated after the liver biopsy diagnosing NASH. Anti-NASH therapies include S-adenosyl methionine (SAMe), milk thistle, and vitamin E at dose of \u2265 400 IU/day; b) Antidiabetic mediation which may impact NASH histology started in the past 12 months including thiazolidinediones (glitazones), dipeptidyl peptidase 4 inhibitors (gliptins) or glucagon-like peptide 1 analogs; c) Immune modulatory agents including systemic steroids, methotrexate, anti-TNF-\u03b1 therapies (infliximab, adalimumab, etanercept) or anti-integrin therapy (namixilab).\n* Self-reported or known marijuana or illicit drug use 30 days before the screening\n* The following laboratory abnormalities within 90 days of screening: a) HbA1C \\> 9.0%, b) Neutrophil count \\< 1.0 x 109/L, c) Platelets \\< 100 109/L, d) Hemoglobin \\< 10 g/dl, e) Albumin \\< 3.5 g, f) Prolonged international normalized ratio (INR), g) Any elevation of bilirubin above normal (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction), h) Serum creatinine \\> 1.5 mg/dl, i) Creatinine clearance \u2264 50 ml/minute calculated by Crockroft-Gault or creatinine \\> 1.5x upper limit of normal\n* Pregnancy or breastfeeding.\n* Women, of childbearing age, who are not willing to practice effective contraception (i.e., barrier, oral contraceptives, or past medical history of hysterectomy) for the 48-week duration of the trial and for 1 month after the first administration of the drug.\n* Participation in an investigational drug study within past 3 months.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Christopher Kigongo",
                    "role": "CONTACT",
                    "phone": "507-266-1998",
                    "email": "Kigongo.Christopher@mayo.edu"
                },
                {
                    "name": "Amy Olofson",
                    "role": "CONTACT",
                    "phone": "507-538-6547",
                    "email": "Olofson.Amy@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Manal Abdelmalek, MD, MPH",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic Minnesota",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Duke University Medical Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Nonalcoholic Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069059",
                    "term": "Atorvastatin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000924",
                    "term": "Anticholesteremic Agents"
                },
                {
                    "id": "D000000960",
                    "term": "Hypolipidemic Agents"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000057847",
                    "term": "Lipid Regulating Agents"
                },
                {
                    "id": "D000019161",
                    "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M351",
                    "name": "Atorvastatin",
                    "asFound": "Out",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21155",
                    "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4243",
                    "name": "Anticholesteremic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4278",
                    "name": "Hypolipidemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M28883",
                    "name": "Lipid Regulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}